Korim Scenarios

Clinical proof becomes the price of expansion

Healthcare & Life Sciences

Clinical proof becomes the price of expansion

Who could capture healthcare AI budgets when clinical proof and integration matter more than a successful demonstration?

Trigger: Clinical evidence, regulatory assurance and record system integration are becoming buying hurdles for healthcare AI. Suppliers face pressure to prove value before wider deployment.

Base case (55%): Evidence gates keep expansion selective

Buyers could expand only those applications with credible clinical results and workable integration. Emerging oversight requirements may add local validation work without stopping every deployment.

  1. First order, 1 to 3 months: Clinical safety leads and procurement teams could require stronger evidence before releasing expansion budgets, increasing work for validation specialists and regulatory advisers.
  2. Second order, 3 to 9 months: Electronic health record suppliers and integration partners could win implementation work, while clinical AI vendors may fund local studies before securing wider contracts.
  3. Third order, 9 to 18 months: Suppliers with verified clinical benefits could gain repeat contracts, while hospital finance directors may tie renewals to measured outcomes rather than software availability.

Acceleration (25%): Local proof becomes a recurring cost

Stricter local validation expectations and uneven clinical results could make assurance a continuing cost. Buyers may demand stronger performance guarantees before extending contracts.

  1. First order, 1 to 3 months: Hospital clinical directors could pause expansion after weak local results, shifting budgets from new licences towards independent testing and clinician oversight.
  2. Second order, 3 to 9 months: Validation providers and specialist regulatory advisers could gain recurring work, while smaller AI suppliers may struggle to finance monitoring and integration obligations.
  3. Third order, 9 to 18 months: Well funded suppliers could absorb evidence costs and win broader contracts, while hospital buyers may lose negotiating options as smaller competitors withdraw.

Retraction (20%): Reusable evidence lowers purchasing hurdles

Clearer assurance expectations and evidence that transfers reliably between hospitals could reduce repeated testing. Standard record system interfaces may let specialist suppliers compete more directly.

  1. First order, 1 to 3 months: Clinical procurement teams could accept reusable validation packages, reducing bespoke assessment work for advisers and allowing specialist vendors to negotiate directly.
  2. Second order, 3 to 9 months: Hospital technology teams could connect more specialist products through standard interfaces, lowering integration fees and weakening record system suppliers' control over purchasing.
  3. Third order, 9 to 18 months: Smaller clinical AI suppliers could gain expansion contracts without large partners, while hospital buyers may regain bargaining power through a wider supplier choice.

Wild card: An unlikely safety failure in a widely used clinical AI application could trigger broad purchasing pauses, moving hospital budgets from expansion to incident reviews and patient follow-up.

Signals to watch

  • Hospital tenders requiring local clinical validation and documented clinician override procedures.
  • Published guidance clarifying evidence, monitoring and change management expectations for clinical AI.
  • Pilot contracts converting into wider deployments after verified clinical outcome reviews.
  • Clinical AI contracts linking payment or renewal to outcomes and native record system integration.

What would change this view

  • Independent studies showing that clinical performance transfers reliably between hospitals without substantial local retesting.
  • Standard integration packages and reusable assurance documents materially reducing the cost of wider deployment.

Scenarios are built from Korim's tracked market signals and refreshed every Monday. Branch weights are indicative judgements, not live forecasts, and are reviewed as new evidence arrives.